Nomura Reiterates Bullish View on Biogen (BIIB) on Tecfidera Sales StreetInsider.com (subscription) "We remain focused on daclizumab Phase III MS data in mid-2014 given its $2bn revenue opportunity and anti-LINGO Phase II optic neuritis data in 4Q14, given its read through to the MS trial (2015E). In a year of regulatory and commercial execution, we ... |
